May 19, 2026By Marian (YoonJee) ChuDaewoong nabs Innovo’s preclinical IBD asset in ₩663B dealDaewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal.
May 14, 2026Epirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in modelsEpirium Bio Inc. has developed a series of small-molecule 15-PGDH inhibitors, the phase II-ready MF-300 and preclinical candidate MF-1305, as potential therapeutics for inflammatory bowel disease (IBD).
May 13, 2026By Marian (YoonJee) ChuDaewoong nabs Innovo’s preclinical IBD asset in ₩663B dealDaewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal.
